國立高雄大學圖資館 |

Language: English

Back

Pediatric cancer therapeutics development

Record Type:	Electronic resources : Monograph/item
Title/Author:	Pediatric cancer therapeutics developmentedited by Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith.
other author:	DiMartino, Jorge.
Published:	Cham :Springer International Publishing :2022.
Description:	vi, 181 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
Subject:	Cancer in childrenTreatment.
Online resource:	https://doi.org/10.1007/978-3-031-06357-2
ISBN:	9783031063572$q(electronic bk.)

Pediatric cancer therapeutics development
Pediatric cancer therapeutics development[electronic resource] /edited by Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith. - Cham :Springer International Publishing :2022. - vi, 181 p. :ill., digital ;24 cm. - Pediatric oncology,2191-0812. - Pediatric oncology..

History of Drug Development -- Target Identification/Validation and Drug Discovery -- Non-Clinical Toxicology -- Study Design and Biostatistics -- Personalized Medicine and Its Impact on Study Design -- Gene and Cellular Therapy -- The Pharma/Biotech Model for Drug Development -- Clinical Research Organizations -- Role of Patients and Advocates in Cancer Therapeutics -- Development -- International Regulatory Agencies -- Ethical Considerations in Cancer Therapeutics Development -- Future Directions: Jorge DiMartino.

This book provides a comprehensive overview of the scientific, medical, regulatory, and economic considerations associated with the discovery, development, and delivery of novel therapeutics for children with cancer. Co-authored by a diverse team from academic, government, and industry backgrounds, the book describes the steps in the process from the identification of a promising therapeutic target to the evaluation of drug candidates in the various phases of clinical testing and regulatory review. Throughout, special emphasis is placed on the unique biology of pediatric malignancies and the medical and social needs of children and their families. In providing a firm grounding in the drug development process, the book will be of value to all with an interest in how medicines currently used to treat pediatric cancer were made available. This includes trainees as well as established practitioners and others participating in translational and clinical research in the academic setting.

ISBN: 9783031063572$q(electronic bk.)

Standard No.: 10.1007/978-3-031-06357-2doiSubjects--Topical Terms:

727620
Cancer in children
--Treatment.

LC Class. No.: RC281.C4

Dewey Class. No.: 618.9299406

Pediatric cancer therapeutics development
LDR:02558nmm a2200337 a 4500 001 633595
003 DE-He213
005 20221118074033.0
006 m d
007 cr nn 008maaau
008 230511s2022 sz s 0 eng d
020 $a 9783031063572$q(electronic bk.)
020 $a 9783031063565$q(paper)
024 7 $a 10.1007/978-3-031-06357-2 $2 doi
035 $a 978-3-031-06357-2
040 $a GP $c GP
041 0 $a eng
050 4 $a RC281.C4
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 618.9299406 $2 23
090 $a RC281.C4 $b P371 2022
245 0 0 $a Pediatric cancer therapeutics development $h [electronic resource] / $c edited by Jorge DiMartino, Gregory H. Reaman, Franklin O. Smith.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2022.
300 $a vi, 181 p. : $b ill., digital ; $c 24 cm.
490 1 $a Pediatric oncology, $x 2191-0812
505 0 $a History of Drug Development -- Target Identification/Validation and Drug Discovery -- Non-Clinical Toxicology -- Study Design and Biostatistics -- Personalized Medicine and Its Impact on Study Design -- Gene and Cellular Therapy -- The Pharma/Biotech Model for Drug Development -- Clinical Research Organizations -- Role of Patients and Advocates in Cancer Therapeutics -- Development -- International Regulatory Agencies -- Ethical Considerations in Cancer Therapeutics Development -- Future Directions: Jorge DiMartino.
520 $a This book provides a comprehensive overview of the scientific, medical, regulatory, and economic considerations associated with the discovery, development, and delivery of novel therapeutics for children with cancer. Co-authored by a diverse team from academic, government, and industry backgrounds, the book describes the steps in the process from the identification of a promising therapeutic target to the evaluation of drug candidates in the various phases of clinical testing and regulatory review. Throughout, special emphasis is placed on the unique biology of pediatric malignancies and the medical and social needs of children and their families. In providing a firm grounding in the drug development process, the book will be of value to all with an interest in how medicines currently used to treat pediatric cancer were made available. This includes trainees as well as established practitioners and others participating in translational and clinical research in the academic setting.
650 0 $a Cancer in children $x Treatment. $3 727620
650 0 $a Cancer $x Chemotherapy. $3 194707
650 0 $a Drug development. $3 190608
700 1 $a DiMartino, Jorge. $3 939580
700 1 $a Reaman, Gregory H. $3 510934
700 1 $a Smith, Franklin O. $3 510935
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
830 0 $a Pediatric oncology. $3 560134
856 4 0 $u https://doi.org/10.1007/978-3-031-06357-2
950 $a Medicine (SpringerNature-11650)